Summary
In human platelets, the effects of various α-adrenergic agonists were studied on platelet aggregation and adenylate cyclase activity. Out of many phenylethylamine derivatives tested, only some catecholamines were able to act as α-adrenergic agonists inducing platelet aggregation and inhibition of adenylate cyclase with the order of potency: adrenaline > noradrenaline>α-methylnoradrenaline. Other phenylethylamine and imidazoline derivatives, which act as potent α-adrenergic agonists in various systems, neither induced primary aggregation nor adenylate cyclase inhibition, when tested at concentrations up to 1 mM. Since binding studies indicated high affinities of these agents to the platelet α-adrenergic receptor, their effects on adrenaline-induced aggregation and adenylate cyclase inhibition were studied.
Both types of α-adrenergic agonists tested, phenylethylamine and imidazoline derivatives, prevented adrenaline-induced aggregation and adenylate cyclase inhibition. The imidazolines, xylometazoline, oxymetazoline, naphazoline, clonidine and tetryzolin, were the most effective antagonists with similar potencies as observed with the typical α-adrenergic antagonists, phentolamine and yohimbine. Phenylethylamine derivatives such as phenylephrine, methoxamine, synephrine and norfenefrine, similarly antagonized the adrenaline-induced responses but higher concentrations were required. The potencies of these phenylethylamine derivatives were similar to those of the classical α-adrenergic antagonists, phenoxybenzamine and azapetine. The results indicate that the platelet α-adrenergic receptor, which has many similarities with the α2-adrenergic receptor with regard to affinities of various α-adrenergic agonists, completely differs from that found in other tissues, inasmuch as only some catecholamines acted as agonists whereas other phenylethylamine derivatives and imidazoline derivatives acted as antagonists.
Similar content being viewed by others
References
Ahlquist, R. P.: A study of the adrenotropic receptors. Am. J. Physiol. 153, 586–600 (1948)
Alexander, R. W., Cooper, B., Handin, R. I.: Characterization of the human platelet α-adrenergic receptor. Correlation of [3H]dihydroergocryptine binding with aggregation and adenylate cyclase inhibition. J. Clin. Invest. 61, 1136–1144 (1978)
Berthelsen, S., Pettinger, W. A.: A functional basis for classification of α-adrenergic receptors. Life Sci. 21, 595–606 (1977)
Born, G. V. R.: Aggregation of human platelets by adenosine diphosphate and its reversal. Nature 194, 927–929 (1962)
Boullin, D. J., Glenton, P. A. M.: Characterization of receptors mediating 5-hydroxytryptamine-and catecholamine-induced platelet aggregation, assessed by the actions of α-and β-blockers, bytyrophenones, 5-HT antagonists and chlorpromazine. Br. J. Pharmacol. 62, 537–542 (1978)
Braunstein, K. M., Sarji, K. E., Kleinfelder, J., Schraibman, H. B., Coldwell, J. A., Eurenius, K.: The effects of dopamine on human platelet aggregation, in vitro. J. Pharmacol. Exp. Ther. 200, 449–457 (1977)
Bygdeman, S., Johnson, O.: Studies on the effects of adrenergic blocking agents on catecholamine induced platelet aggregation and uptake of noradrenaline and 5-hydroxytryptamine. Acta Physiol. Scand. 75, 129–138 (1969)
Cambridge, D., Davey, M. J., Massingham, R.: Prazosin, a selective antagonist of postsynaptic α-adrenoceptors. Br. J. Pharmacol. 59, 514P-515P (1977)
Cheng, Y.-C. Prusoff, W. H.: Relationship between the inhibition constant (K 1) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099–3108 (1973)
Jakobs, K. H.: Synthetic α-adrenergic agonists are potent α-adrenergic blockers in human platelets. Nature 274, 819–820 (1978)
Jakobs, K. H., Rauschek, R.: [3H]Dihydroergonine binding to α-adrenergic receptors in human platelets. Klin. Wschr. 56, (Suppl. I), 139–145 (1978)
Jacobs, K. H., Saur, W., Schultz, G.: Reduction of adenylate cyclase activity in lysates of human platelets by the alpha-adrenergic component of epinephrine. J. Cycl. Nucl. Res 2, 381–392 (1976)
Jakobs, K. H., Saur, W., Schultz, G.: Inhibition of platelet adenylate cyclase by epinephrine requires GTP. FEBS Lett. 185, 167–170 (1978a)
Jakobs, K. H., Saur, W., Schultz, G.: Characterization of α-and β-adrenergic receptors linked to human platelet adenylate cyclase. Naunyn-Schmiedeberg's Arch. Pharmacol. 302, 285–291 (1978b)
Kafka, M. S., Tallmann J. F., Smith, C. C.: Alpha-adrenergic receptors in human platelets. Life Sci. 21, 1429–1438 (1977)
Lands, A. M., Arnold, A., McAuliff, J. P., Luduena, F. P., Brown, T. G.: Differentiation of receptor systems activated by sympathomimetic amines. Nature 214, 597–598 (1967)
Langer, S. Z.: Presynaptic regulation of catecholamine release. Biochem. Pharmacol. 23, 1793–1800 (1974)
Lowry, O. H., Rosebrough, N. J., Farr, A. L., Randall, R. J.: Protein measurement with the Folin phenol reagent J. Biol. Chem. 193, 265–275 (1951)
Mills, D. C. B., Roberts, G. C. K.: Effects of adrenaline on human blood platelets. J. Physiol. (Lond.) 193, 443–453 (1967)
Newman, K. D., Williams, L. T., Bishopric, N. H., Lefkowitz, R. J.: Identification of α-adrenergic receptors in human platelets by [3H]dihydroergocryptine binding J. Clin. Invest. 61, 395–402 (1978)
O'Brien, J. R.: Some effects of adrenaline and anti-adrenaline compounds on platelets in vitro and in vivo. Nature 200, 763–764 (1963)
O'Brien, J. R.: A comparison of platelet aggregation by seven compounds and a comparison of their inhibitors. J. Clin. Pathol. 17, 275–281 (1964)
Sneddon, J. M.: Blood platelets as a model for monoamine-containing neurones. In: Progress in neurobiology, vol. 1 (G. A. Kerkut and J. W. Phillis, eds.), pp. 151–198. Oxford: Pergamon Press 1973
Starke, K.: Alpha sympathomimetic inhibition of adrenergic and cholinergic transmission in the rabbit heart. Naunyn-Schmiedeberg's Arch. Pharmacol. 274, 18–45 (1972)
Starke, K., Montel, H., Gayk, W., Merker, R.: Comparison of the effects of clonidine on pre-and postsynaptic adrenoceptors in rabbit pulmonary artery. α-Sympathomimetic inhibition of neurogenic vasoconstriction. Naunyn-Schmiedeberg's Arch. Pharmacol. 285, 133–150 (1974)
Starke, K., Endo, T., Taube, H. D.: Relative pre-and postsynaptic potencies of α-adrenoceptor agonists in the rabbit pulmonary artery. Naunyn-Schmiedeberg's Arch. Pharmacol. 291, 55–78 (1975)
Author information
Authors and Affiliations
Additional information
A preliminary report of these studies has been presented (Jakobs, 1978)
Rights and permissions
About this article
Cite this article
Lasch, P., Jakobs, K.H. Agonistic and antagonistic effects of various α-adrenergic agonists in human platelets. Naunyn-Schmiedeberg's Arch. Pharmacol. 306, 119–125 (1979). https://doi.org/10.1007/BF00498981
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00498981